A review of continuous glucose monitoring published this year in JAMA Internal Medicine reached a conclusion that sits awkwardly against how these devices are now marketed. In people who do not have diabetes, the authors found no scientific evidence that wearing a continuous glucose monitor improves health or prevents disease. Not weak evidence. No trials showing it.

This matters because the sensors moved from prescription-only to retail shelves quickly, and the people buying them are frequently the most engaged users of health information: metabolically healthy, curious, willing to change behavior based on a number. That combination is exactly what makes an uninterpretable measurement expensive rather than harmless.

From the Lab to the Ledger

A continuous glucose monitor does not measure blood glucose. It measures glucose in the interstitial fluid just under the skin, and infers a blood value through an algorithm, which is why a reading lags an actual blood change by several minutes and why two sensors on the same person at the same time can disagree. In diabetes care, where the question is whether glucose is dangerously high or dangerously low, that resolution is plenty. The clinical value there is well established, especially for anyone on insulin or at risk of a hypoglycemic episode.

The problem is what happens when you take a tool built to catch a large abnormal signal and ask it to grade a normal one. In a person without diabetes, glucose moves constantly, rising after meals and settling on its own, and current research shows that healthy people routinely have readings they would be alarmed by if they saw them on a screen. Nobody has established what pattern within the normal range predicts a better or worse outcome, which is why the review's central point is not that the readings are wrong but that there is no evidence base for acting on them.

That gap creates a specific failure mode, and it is the one clinicians describe most often. A user sees a spike after a piece of fruit and drops the fruit for something that produces a flatter line but a worse nutritional profile. The measurement is real, the interpretation is invented, and the substitution moves in the wrong direction. Anxiety works the same way: a normal fluctuation reads as a warning, and the response is to restrict, not to improve.

There is also an opportunity cost that gets less attention. Attention spent optimizing a curve that has not been shown to matter is attention not spent on measures that have: blood pressure, lipids, sleep duration, muscle mass, and how much someone actually moves. Those have decades of outcome data behind them, and none of them stream to a phone every five minutes.

Bio-Pipeline Ledger

CGM in type 1 diabetes and insulin-treated type 2 diabetes: well validated and standard of care, with clear benefit in avoiding dangerous highs and lows.

CGM in non-insulin-treated type 2 diabetes: supported by evidence for a modest improvement in average glucose control, and useful for guiding treatment adjustments. Real, and smaller than the marketing suggests.

CGM in people without diabetes: no trial evidence of improved health outcomes. This is the finding of the 2026 review, and it applies to the entire retail category.

Standard cardiometabolic screening, including fasting glucose and HbA1c: validated, inexpensive, and the tool that actually identifies developing metabolic disease. It is the test being skipped when a sensor substitutes for a clinic visit.

Using a CGM as a short, self-funded experiment to see how specific meals behave: reasonable as personal curiosity, with no claim attached. The line worth holding is between a two-week experiment and a permanent monitoring habit built on an evidence base that does not exist.

The Clinical Reality Check

The verified takeaway is narrow: these devices work as instruments and are genuinely valuable in diabetes care, and there is no published evidence that continuous monitoring improves health in people who do not have diabetes. Both halves of that are true at once, and the marketing tends to borrow the credibility of the first half for the second.

What is overstated is the idea that more data about a normal physiological process is automatically better. A measurement becomes useful when there is an established action attached to a specific reading. Until someone runs the trials showing which glucose patterns in healthy people predict which outcomes, and what changing them accomplishes, the readings are observations rather than guidance.

The practical position is not abstinence, it is proportion. If the sensor is interesting, wear one for a couple of weeks and learn something about your own responses, then take that curiosity to the measures with outcome data behind them. And if a reading genuinely worries you, the next step is a standard blood test ordered by a clinician, not a tighter diet built around a curve.